Answers are grounded in this paper and cite their sources.
Electronic cigarette (e-cigarettes) use has risen exponentially since their invention in China in the early 2000s [1]. Vaping, often promoted as a smoking cessation aid, is often considered a healthier, cleaner and cheaper alternative to tobacco smoking. Aggressive marketing, a wide range of flavours and ‘safer’ user profile have contributed to increased uptake amongst the youth and even non-smokers [1]. However, emerging evidence regarding the toxic constituents and the lack of regulation of e-cigarettes has generated concern over their safety profile [1]. In this editorial, we highlight the emerging vascular implications of vaping and its potential relevance to microvascular disorders frequently encountered in rheumatology, including Raynaud’s phenomenon, chilblains, and thromboangiitis obliterans (Buerger’s disease). Traditional cigarettes are composed of tobacco, chemical additives, a filter and a paper wrapper [2]. Burning tobacco generates over 7000 chemicals, including, nitrogen, oxygen, carbon dioxide, carbon monoxide, water, argon, hydrogen, acetone, nitrogen oxides and volatile sulphur compounds, amongst others. Several hundred of these chemicals are known to be toxic, with numerous also being carcinogenic [2]. In contrast, e-cigarettes consist of a cartridge filled with liquid, an atomizer, the mouthpiece and a rechargeable battery [3]. Common components of the liquid include propylene glycol, glycerol, flavourings, vitamin E additives and tetrahydrocannabinol (THC). Additionally, nicotine may also be present, although some devices are nicotine free. The atomizer heats the liquid solution creating an inhalable aerosol. Comparable to tobacco combustion, this produces new potentially hazardous compounds including propylene oxide, acrolein, reactive aldehydes, metal particles, silicate particles, ultrafine particles and reactive oxidative species [3]. Concerningly, the exact composition demonstrates significant variability based on the liquid, device and user pattern [1, 3]. While the health risks of traditional cigarette smoking are well-established, the long-term safety profile of vaping is largely unknown as it has not been subjected to comparable rigorous scientific scrutiny. Table 1 demonstrates some of the similarities and differences between traditional smoking and vaping. Comparison of traditional cigarette smoking and vaping with respect to vascular and systemic biological effects relevant to microvascular disease. Emerging research has showcased the adverse effects of e-cigarettes on several organ systems, particularly affecting respiratory and cardiovascular health [3–5]. The 2019 outbreak of E-cigarette or Vaping Use-Associated Lung Injury (EVALI) in the USA has been the largest health concern directly associated with vaping. Vitamin E acetate, an additive found in some THC-containing vaping products, has been strongly implicated in cases of EVALI [5]. The negative vascular implications of cigarette smoking are well recognized. Vaping has deleterious effects on vascular health through sympathetic activation and vasoconstriction [4], endothelial dysfunction and oxidative stress [3] and finally inflammation and thrombogenicity [6]. Sympathetic activation is primarily triggered by nicotine-stimulated factors. Nicotine promotes catecholamine release thereby increasing heart rate and contractility. Nicotine further provokes vasoconstriction, which causes increased blood pressure and reduced wound healing [4]. However, a recent study assessing the effects of traditional cigarettes compared with e-cigarettes in mice found vasoconstriction was not nicotine-dependent [7]. This raises concern about toxic metabolites found in e-cigarettes which independently affect vascular health. Nitric oxide is important in maintaining endothelial structure and function, and mediating vasodilatation [3, 4]. E-cigarette aerosols trigger the release of reactive oxygen species and reactive aldehydes which results in oxidative stress and inflammation of the blood vessels [4] and a reduction in production and availability of nitric oxide [3, 4]. Vaping-induced immune system activation with recruitment of monocytes and other phagocytic cells contributes to endothelial damage [6]. Both ultrafine particles and propylene glycol induce a chronic inflammatory state and also cause airway irritation and increased resistance [6, 8]. This study also reported significant dual usage (of conventional cigarettes and vaping devices) and dual use was associated with lower (poorer) general health scores (adjusted P =0.002) and higher (poorer) past month breathing difficulty scores (adjusted P=0.001) [8]. Interestingly, one study found e-cigarettes were associated with increased vascular permeability compared with conventional cigarettes [9]. They also reported increased risk of coronary heart disease, arrhythmia, chest pain or palpitations and increased breathing issues, chronic lung disease and acute lung injury [9]. A recently published systematic review identified several risks relating to many different organ systems with vaping including association with an increased risk of stroke (OR 1.25, 95% CI 1.1–1.55) [10]. The cumulative effects on heart rate, blood pressure, endothelial and platelet functions, and increased oxidative stress have been recognized across different studies and contribute to the cardiovascular outcomes. There is also increased asthma risk (OR 1.30, 95% CI 1.17–1.45) which persists even after discontinuation. Similarly, there are significant effects of vaping on neurological and other systems with the US Food and Drug Authority (FDA) recognizing seizures, tremors and syncope as reported adverse events. The levels of heavy metals in aerosols from vaping are reportedly higher than those in traditional cigarette smoke [10]. Data suggest neuroinflammation in both central and peripheral nervous systems and vaping plays a role in thrombosis by influencing platelet activity, increasing the secretion and aggregation of platelet microparticles and affecting soluble P-selectin levels [10]. Raynaud’s and chilblains are vasospastic conditions affecting the extremities. Raynaud’s phenomenon is classically described as a triphasic temporary discolouration (typically white to blue to red) and shows increased prevalence amongst the young and female population [11]. Thromboangiitis obliterans (Buerger’s disease) is a nonatherosclerotic, inflammatory vascular disorder that affects small and medium-sized arteries and veins [12]. Like Raynaud’s and chilblains, it most commonly involves the distal extremities, leading to segmental vessel occlusion and ischaemia. Cigarette smoking is a well-established risk factor for Raynaud’s, chilblains and Buerger’s; however, there is very limited evidence assessing the effect of vaping with these conditions. As described earlier, there are several mechanistic reasons why vaping can result in adverse microvascular health. Prolonged vaping and resultant chronic inflammation may contribute to worsening of localized vasculitis in chilblains and Buerger’s disease, given the immune cell activation. Importantly, a recently published case report described progression of Buerger’s disease in a patient with no active conventional tobacco exposure, but heavy e-cigarette use, providing emerging clinical evidence that vaping alone may trigger or exacerbate Buerger’s disease [10]. Microvascular tone and endothelial integrity are critical determinants of digital perfusion. Any exposure that augments vasospasm, endothelial dysfunction or thrombogenicity may therefore plausibly exacerbate conditions such as Raynaud’s phenomenon and chilblains. Anecdotally, we and others have observed cases of digital ischaemia in young adults with significant vaping exposure that improved following cessation alongside standard vasodilator therapy. While such observations are not proof of causality, they further highlight the need for systematic investigation. As vaping prevalence continues to rise, particularly among younger populations, its potential impact on vascular health deserves greater attention within rheumatology. Although long-term epidemiological data remain limited, emerging mechanistic and clinical evidence suggests that vaping may contribute to endothelial dysfunction, vasospasm and pro-thrombotic states. These processes overlap closely with the pathophysiology of Raynaud’s phenomenon, chilblains and Buerger’s disease. Routine enquiry about vaping exposure should therefore become part of vascular and rheumatology history taking, and future research is urgently required to clarify its role in microvascular disease. No new data were generated or analysed for this letter. All information supporting the views expressed is derived from previously published sources, as cited in the reference list. No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript. Disclosure statement: S.D.: advisory boards: AbbVie and Boehringer Ingelheim. The other authors have declared no conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Amin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: